Clinical Trial Initiated for Bundibugyo Ebola Strain Treatment
A new clinical trial has launched in the DRC to test targeted treatments for the Bundibugyo Ebola strain, which currently has no vaccine or approved therapy.
Atlas Newsdesk ·
A clinical trial has commenced in the Democratic Republic of the Congo to evaluate targeted treatments for the Bundibugyo strain of the Ebola virus. This strain currently lacks both a preventive vaccine and an approved therapeutic, leaving healthcare providers reliant on supportive care measures.
The trial, designated as the Platform adaptive randomized trial for new and repurposed Filovirus treatments (PARTNERS), is assessing the efficacy of the monoclonal antibody MBP134, the antiviral remdesivir, and a combination of both. These therapies were selected based on existing safety data and their potential to neutralize multiple Ebolavirus species.
Coordinated by international research institutions and regional health
Coordinated by international research institutions and regional health authorities, the platform trial is designed to allow for the rapid integration of additional therapeutic candidates as evidence emerges. The study aims to improve survival rates in an outbreak that has already resulted in over 1,500 confirmed cases and 500 deaths.
Results are expected within several months to one year, depending on enrollment rates and the progression of the outbreak. The trial represents a critical effort to mitigate the public health impact of a strain that has historically lacked specific medical countermeasures.